Chen-yang Ye
No. 415 Fengyang Road
Shanghai, 200003, China
Shanghai, 200003, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Anlotinib plus sintilimab as first-line treatment for patients with advanced colorectal cancer (APICAL-CRC): an open-label, single-arm, phase II trial.
Journal: Signal transduction and targeted therapy
Published: January 12, 2025
Anlotinib plus toripalimab as a first-line treatment in patients with advanced gastric cancer and performance status 2: the phase II APICAL-GC trial.
Journal: Nature communications
Published: January 05, 2025
The sub-arc mantle has remained oxidized since the Neoproterozoic oxygenation event.
Journal: Nature communications
Published: October 14, 2024
Membrane-associated RING-CH protein (MARCH8) is a novel glycolysis repressor targeted by miR-32 in colorectal cancer.
Journal: Journal of translational medicine
Published: February 14, 2022
Cetuximab and vemurafenib plus FOLFIRI (5-fluorouracil/leucovorin/irinotecan) for BRAF V600E-mutated advanced colorectal cancer (IMPROVEMENT): An open-label, single-arm, phase II trial.
Journal: European journal of cancer (Oxford, England : 1990)
Published: November 17, 2021
Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring PRRC2B-ALK Rearrangement: A Case Report.
Journal: Frontiers in oncology
Published: August 20, 2021
The Role of Dynamic ctDNA Monitoring During Combination Therapies of BRAF V600E-Mutated Metastatic Colorectal Cancer: A Case Report.
Journal: OncoTargets and therapy
Published: June 17, 2020
A meta-analysis of efficacy and safety of S-1 monotherapy or combination therapy as first-line treatment in metastatic colorectal cancer.
Journal: International journal of colorectal disease
Published: April 13, 2020
Showing 1-8 of 8
Last Updated: 09/26/2026